Identifying pathogenic proteins leads to potential new treatments for diseases such as diabetes.

Published Date: 02 Mar 2023

New research has identified hundreds of proteins that can lead to the development of metabolic diseases, such as type 2 diabetes mellitus, and therefore have treatment potential.

Read Full News

Latest News

Time-Restricted Eating Reshapes Gut Flora, Aids Weight Loss

Time-restricted eating alters the gut microbiota and serum metabolite profiles in young adults with overweight or obesity, with changes linked to weight loss and improved cardiometabolic health.

Tirzepatide Raises Thyroid Risk in Certain At-Risk Patients

Patients with end-stage renal disease or preexisting thyroid disease are more likely to experience either a new thyroid problem or a worsening of their thyroid disease while on tirzepatide.

Is It Time to Talk to Patients About Bowel Hygiene?

Advising patients about bowel hygiene is on the rise as understanding grows about the multifaceted nature of GI disorders.

France Becomes First EU Country to Reimburse Anti-obesity Drugs, Minister Says

France will reimburse the cost of weight-loss drugs prescribed to severely obese patients from mid-June in a ⁠first for a European Union country, Health Minister Stephanie...

Use of Common Food Colours Tied to High Type 2 Diabetes Risk

A higher intake of several food colouring additives is associated with an increased risk of developing type 2 diabetes, an analysis of the French NutriNet-Santé cohort shows.

CVS Brings Back Coverage for Lilly's Obesity Drug Zepbound

CVS Health will restore Eli Lilly's weight-loss injection Zepbound to its list of covered drugs and add the drugmaker's newly approved obesity pill, Foundayo, ⁠it said on...

Todays Updates

Psychotropics Linked to Increased BMI, CVD Risk

Psychotropics are associated with increased BMI, and users with a high BMI genetic risk score and an unhealthy lifestyle have triple the risk for CVD, new research shows.

Tafasitamab Combo Boosts R-CHOP in Frontline DLBCL

Tafasitamab and lenalidomide are likely to be approved with R-CHOP for frontline DLBCL, but with bispecific antibodies on the horizon, the role of the combination is uncertain.

Abemaciclib Slows Progression of Advanced Liposarcoma

In a phase 3 trial of patients with dedifferentiated liposarcoma, the CDK4/6 inhibitor extended progression-free survival more than sixfold.

Therapy Combo Improves Radiographic PFS in Prostate Cancer

A phase 3 trial evaluates a PARP inhibitor or placebo plus an androgen pathway inhibitor to treat men with advanced prostate cancer associated with genetic changes.

Teclistamab Alone Ups Previously Treated Myeloma Survival

In the first phase 3 trial of teclistamab monotherapy, the bispecific antibody was associated with better PFS and OS than standard regimens in relapsed or refractory multiple myeloma.

Trial Supports Ivonescimab and Chemo for NSCLC Survival

A phase 3 trial evaluates the safety and efficacy of an investigational bispecific antibody with chemotherapy compared to standard treatment in advanced squamous NSCLC.

Asandeutertinib Tops Osimertinib for NSCLC With Brain Mets

In an interim analysis of a randomized phase 2 trial, asandeutertinib improved intracranial response and intracranial PFS vs osimertinib in patients with EGFR-mutated NSCLC with brain metastases.

Todays Updates

Psychotropics Linked to Increased BMI, CVD Risk

Psychotropics are associated with increased BMI, and users with a high BMI genetic risk score and an unhealthy lifestyle have triple the risk for CVD, new research shows.

Tafasitamab Combo Boosts R-CHOP in Frontline DLBCL

Tafasitamab and lenalidomide are likely to be approved with R-CHOP for frontline DLBCL, but with bispecific antibodies on the horizon, the role of the combination is uncertain.

Abemaciclib Slows Progression of Advanced Liposarcoma

In a phase 3 trial of patients with dedifferentiated liposarcoma, the CDK4/6 inhibitor extended progression-free survival more than sixfold.

Therapy Combo Improves Radiographic PFS in Prostate Cancer

A phase 3 trial evaluates a PARP inhibitor or placebo plus an androgen pathway inhibitor to treat men with advanced prostate cancer associated with genetic changes.

Teclistamab Alone Ups Previously Treated Myeloma Survival

In the first phase 3 trial of teclistamab monotherapy, the bispecific antibody was associated with better PFS and OS than standard regimens in relapsed or refractory multiple myeloma.

Trial Supports Ivonescimab and Chemo for NSCLC Survival

A phase 3 trial evaluates the safety and efficacy of an investigational bispecific antibody with chemotherapy compared to standard treatment in advanced squamous NSCLC.

Asandeutertinib Tops Osimertinib for NSCLC With Brain Mets

In an interim analysis of a randomized phase 2 trial, asandeutertinib improved intracranial response and intracranial PFS vs osimertinib in patients with EGFR-mutated NSCLC with brain metastases.

Latest News

Time-restricted eating alters the gut microbiota and serum metabolite profiles in young adults with overweight or obesity, with changes linked to weight loss and improved cardiometabolic health.

Patients with end-stage renal disease or preexisting thyroid disease are more likely to experience either a new thyroid problem or a worsening of their thyroid disease while on tirzepatide.

Advising patients about bowel hygiene is on the rise as understanding grows about the multifaceted nature of GI disorders.

France will reimburse the cost of weight-loss drugs prescribed to severely obese patients from mid-June in a ⁠first for a European Union country, Health Minister Stephanie...

A higher intake of several food colouring additives is associated with an increased risk of developing type 2 diabetes, an analysis of the French NutriNet-Santé cohort shows.

CVS Health will restore Eli Lilly's weight-loss injection Zepbound to its list of covered drugs and add the drugmaker's newly approved obesity pill, Foundayo, ⁠it said on...

News All Time

GLP-1s Tied to Weight Loss in Real-World Rheumatologic Care

Semaglutide and tirzepatide use is rising among patients with rheumatic and musculoskeletal diseases and is linked to meaningful 1-year weight loss, especially in tirzepatide users.

FRAX Predicts Surgery Benefit in Hyperparathyroidism

The Fracture Risk Assessment Tool predictions suggest patients who don’t meet guideline criteria for parathyroidectomy may nevertheless benefit from the surgery.

Serum Acylcarnitines May Predict Kidney Decline in Diabetes

Specific serum acylcarnitine levels are linked to faster kidney function decline in type 2 diabetes and can help improve the prediction of patients at highest risk for rapid decline.

Tirzepatide Yields Early Weight Loss, Later Plateau

Modeling finds marked early weight loss with tirzepatide that later plateaus as appetite returns and energy expenditure decreases, and discontinuation of the drug is linked to partial weight regain.

The Sweetener Trap: Are Sugar Alternatives Backfiring?

Emerging evidence suggests some sugar substitutes may affect metabolism, gut microbiome, and cardiovascular health more than previously recognized.

Stigma Negatively Affects Postbariatric Outcomes

Weight bias, stigma, and discrimination are linked to poorer mental health and weight outcomes after bariatric surgery, although the long-term physical effects remain understudied.

Bayer Says FDA Grants Priority Review Designation for Finerenone

Bayer said on Thursday ⁠that the U.S. Food and ⁠Drug Administration had accepted its ⁠supplemental New ‌Drug Application for finerenone and granted priority review...

BioMarin's Drug Shows Significant Growth Gains in Children in Late-stage Trial

BioMarin Pharmaceutical said on Wednesday its treatment for a rare condition that ⁠leads to short stature helped boost growth in children, meeting the main goal of a...

Diabetic Peripheral Neuropathy Tied to Dementia Risk in T2D

Diabetic peripheral neuropathy above a certain vibration perception threshold is linked to a notably higher risk for dementia in patients with type 2 diabetes, according to a Danish cohort study.

Finding the Next Weight-Loss Drug in Python Blood

Pythons can go weeks without eating. Now researchers have isolated an appetite-suppressing metabolite in python blood that could spur a new weight-loss therapy.

Diabetes Meds Show Varied Associations With Liver Protection

Different antidiabetic drug classes show distinct associations with the risk for major adverse liver outcomes among patients with type 2 diabetes, according to a network meta-analysis.

Could Digital Obesity Care Help Improve the Economy?

A UK digital obesity programme was associated with > 40% fewer GP visits and markedly lower long-term sick leave within 9 months in a real-world analysis.

CGM Reduces Complications, Mortality in T1D

Continuous glucose monitoring was associated with substantial reductions in diabetes-related complications and mortality in adults with type 1 diabetes in a large national study.

A Practical Guide to Make Digital Tools Work With GLP-1s

The learning curve can be steep for patients trying apps, wearables, and telehealth platforms. Your expertise is needed.

Diabetes Linked to Increased Cancer Risk in Hispanic Adults

Researchers determine time-varying diabetes measures and cancer incidence over time from a US multisite, prospective cohort study involving 16,415 Hispanic and Latino adults aged 18-74 years.

GLP-1s Curb Hunger; Snacks Keep Blood Sugar Stable

If three meals a day is too much, patients can turn to healthy snacks.

Recommended News For You

Cancer deaths expected to rise to over 18 million in 2050, nearly 75% more than in 2024

Lentiviral Gene Therapy Shows Promise in Severe Hemophilia A

combating racial discrimination in next-generation breast cancer screening.

Pretreatment Liver Tests Often Overlooked in CDK4/6 Therapy

Renewing the call for a national Cancer Patient's Bill of Rights

Durvalumab Plus BCG Earns FDA Nod for Bladder Cancer

FINAL USPSTF RECOMMENDATIONS ON ANXIETY, DEPRESSION, AND SUIICIDAL RISK.

Recommended Articles For You

CAR T-Cell Therapy: Revolutionizing Hematologic Malignancies 

The Importance of Understanding Your D-Dimer Levels: A Comprehensive Guide 

The Pivotal Role of Telomerase in Breast Cancer Therapy Resistance and Treatment Strategies 

Octreotide's Efficacy in Reducing Transfusion Requirements in Angiodysplasia Bleeding 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Key mechanism behind prostate cancer drug resistance reveals potential new treatment strategy

2.

Breast cancer prevention: How nurse practitioners and physician assistants can help

3.

There is a 40% reduction in the risk of 9 cancers with good cardiorespiratory fitness.

4.

Liver cancer survival rates reflect income disparities

5.

In cases of locally advanced, potentially curable pancreatic cancer, a combination of drugs enhances the results of radiation therapy.

1.

Unraveling the Mysteries of Metastasis: Exploring the Latest Advances in Cancer Research

2.

The Miracle of Tenecteplase: How This Drug Is Saving Lives

3.

The Importance of Iron Rich Foods in Preventing and Treating Anemia 

4.

Chloride Test in HCC: Diagnostic Utility, Prognostic Role, and Emerging Insights

5.

The Science Behind Imatinib: How It Targets Cancer Cells 

1.

International Lung Cancer Congress®

2.

Genito-Urinary Oncology Summit 2026

3.

Future NRG Oncology Meeting

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part VII

2.

Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part I

3.

Current Scenario of Cancer- Q&A Session to Close the Gap Part II

4.

A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part V

5.

Evolving Space of First-Line Treatment for Urothelial Carcinoma- Case Discussion

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot